Approaches to produce and characterize recombinant protein VP1-2A of HAV for serological rapid test application.

[1]  M. Kumar,et al.  Oligomers of hepatitis A virus (HAV) capsid protein VP1 generated in a heterologous expression system , 2022, Microbial Cell Factories.

[2]  Gabriel Menezes Costa dos Santos,et al.  Detection of Antibodies against Hepatitis A Virus (HAV) by a Surface Plasmon Resonance (SPR) Biosensor: A New Diagnosis Tool Based on the Major HAV Capsid Protein VP1 (SPR-HAVP1) , 2021, Sensors.

[3]  S. Gobec,et al.  Analytical Techniques for Structural Characterization of Proteins in Solid Pharmaceutical Forms: An Overview , 2021, Pharmaceutics.

[4]  O. Spadiut,et al.  High pressure homogenization is a key unit operation in inclusion body processing. , 2020, Journal of biotechnology.

[5]  Ali Choopani,et al.  Expression, solubilization, refolding and final purification of recombinant proteins as expressed in the form of "classical inclusion bodies" in E. coli. , 2020, Protein and peptide letters.

[6]  Hehe Lv,et al.  DLS: A Link Prediction Method Based on Network Local Structure for Predicting Drug-Protein Interactions , 2020, Frontiers in Bioengineering and Biotechnology.

[7]  J. Halpern,et al.  Application of Voltage in Dynamic Light Scattering Particle Size Analysis. , 2020, Journal of visualized experiments : JoVE.

[8]  R. Varadarajan,et al.  Facile measurement of protein stability and folding kinetics using a nano differential scanning fluorimeter , 2019, Protein science : a publication of the Protein Society.

[9]  S. Lemon,et al.  Hepatitis A Virus Genome Organization and Replication Strategy. , 2018, Cold Spring Harbor perspectives in medicine.

[10]  G. Xia,et al.  Notes from the Field: Increase in Reported Hepatitis A Infections Among Men Who Have Sex with Men — New York City, January–August 2017 , 2017, MMWR. Morbidity and mortality weekly report.

[11]  M. Medeiros,et al.  Recombinant VP1 protein as a potential marker for the diagnosis of acute hepatitis A virus infection. , 2017, Journal of virological methods.

[12]  M. Edelstein,et al.  Outbreak of hepatitis A associated with men who have sex with men (MSM), England, July 2016 to January 2017 , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  M. Medeiros,et al.  Solubility as a limiting factor for expression of hepatitis A virus proteins in insect cell-baculovirus system , 2016, Memorias do Instituto Oswaldo Cruz.

[14]  A. B. Reis,et al.  Multi-antigen print immunoassay (MAPIA)-based evaluation of novel recombinant Leishmania infantum antigens for the serodiagnosis of canine visceral leishmaniasis , 2015, Parasites & Vectors.

[15]  D. Chung,et al.  Expression and immunogenic analysis of recombinant polypeptides derived from capsid protein VP1 for developing subunit vaccine material against hepatitis A virus. , 2014, Protein expression and purification.

[16]  Masaya Miyazaki,et al.  Refolding Techniques for Recovering Biologically Active Recombinant Proteins from Inclusion Bodies , 2014, Biomolecules.

[17]  C. Meng,et al.  High yield expression of duck hepatitis A virus VP1 protein in Escherichia coli, and production and characterization of polyclonal antibody. , 2013, Journal of virological methods.

[18]  B. Strukelj,et al.  Expression of a hepatitis A virus antigen in Lactococcus lactis and Escherichia coli and evaluation of its immunogenicity , 2013, Applied Microbiology and Biotechnology.

[19]  K. Kim,et al.  Expression of a recombinant chimeric protein of hepatitis A virus VP1-Fc using a replicating vector based on Beet curly top virus in tobacco leaves and its immunogenicity in mice , 2011, Plant Cell Reports.

[20]  L. Foti,et al.  Development of a Multiplex Bead-Based Assay for Detection of Hepatitis C Virus , 2011, Clinical and Vaccine Immunology.

[21]  Patrick Garidel,et al.  Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development , 2010, Pharmaceutical Research.

[22]  R. Komel,et al.  Isolation of biologically active nanomaterial (inclusion bodies) from bacterial cells , 2010, Microbial cell factories.

[23]  M. Vijayalakshmi,et al.  Evaluation of Immobilized Metal-Ion Affinity Chromatography (IMAC) as a Technique for IgG1 Monoclonal Antibodies Purification: The Effect of Chelating Ligand and Support , 2010, Applied biochemistry and biotechnology.

[24]  T. Graule,et al.  Isoelectric points of viruses , 2009, Journal of applied microbiology.

[25]  S. Goldenberg,et al.  Viability study of a multiplex diagnostic platform for Chagas disease. , 2009, Memorias do Instituto Oswaldo Cruz.

[26]  I. Chung,et al.  Expression and immunogenicity of recombinant polypeptide VP1 of human hepatitis A virus in stably transformed fruitfly (Drosophila melanogaster) Schneider 2 cells , 2009, Biotechnology and applied biochemistry.

[27]  Sudhir Sahdev,et al.  Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies , 2007, Molecular and Cellular Biochemistry.

[28]  A. Bosch,et al.  Codon usage and replicative strategies of hepatitis A virus. , 2007, Virus research.

[29]  R. Galler,et al.  Genetic variability of hepatitis A virus strain HAF-203 isolated in Brazil and expression of the VP1 gene in Escherichia coli. , 2006, Memorias do Instituto Oswaldo Cruz.

[30]  Xiaomei Yan,et al.  Multiplexed flow cytometric immunoassay for influenza virus detection and differentiation. , 2005, Analytical chemistry.

[31]  S. Dunbar.  Applications of Luminex® xMAP™ technology for rapid, high-throughput multiplexed nucleic acid detection , 2005, Clinica Chimica Acta.

[32]  H. P. Sørensen,et al.  Advanced genetic strategies for recombinant protein expression in Escherichia coli. , 2005, Journal of biotechnology.

[33]  M. Gennaro,et al.  A multi-antigen print immunoassay for the development of serological diagnosis of infectious diseases. , 2000, Journal of immunological methods.

[34]  V. Gauss-Müller,et al.  Intrinsic Signals for the Assembly of Hepatitis A Virus Particles , 1999, The Journal of Biological Chemistry.

[35]  S. Perlman,et al.  Recombinant Hepatitis A Virus Antigen: Improved Production and Utility in Diagnostic Immunoassays , 1998, Journal of Clinical Microbiology.

[36]  R J Fulton,et al.  Advanced multiplexed analysis with the FlowMetrix system. , 1997, Clinical chemistry.

[37]  S. Duddu,et al.  Effect of Glass Transition Temperature on the Stability of Lyophilized Formulations Containing a Chimeric Therapeutic Monoclonal Antibody , 1997, Pharmaceutical Research.

[38]  T. Powdrill,et al.  Immunologic priming with recombinant hepatitis A virus capsid proteins produced in Escherichia coli , 1991, Journal of virology.

[39]  Zhou Mingquan,et al.  Recombinant proteins VP1 and VP3 of hepatitis A virus prime for neutralizing response , 1990, Journal of medical virology.

[40]  J. M. Johnston,et al.  Antigenic and immunogenic properties of a hepatitis A virus capsid protein expressed in Escherichia coli. , 1988, The Journal of infectious diseases.

[41]  E. Winnacker,et al.  Expression of hepatitis A virus cDNA in Escherichia coli: antigenic VP1 recombinant protein , 1987, Journal of virology.

[42]  G. Weber,et al.  Ultraviolet fluorescence of the aromatic amino acids. , 1957, The Biochemical journal.

[43]  P. Malani,et al.  Hepatitis A. , 2017, JAMA.

[44]  P. van Damme,et al.  Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. , 2017, Journal of hepatology.

[45]  W. Brondyk.  Selecting an appropriate method for expressing a recombinant protein. , 2009, Methods in enzymology.